Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Director · Chief Executive Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,682 |
Ending reported balance
After 2026-01-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-02 · Exercise / conversion · Acquired 1,360 · Balance 5,382 F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Row 2 · 2026-01-02 · Sale · Disposed 700 · Balance 4,682 F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,640 |
Reported balance
After 2026-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-02 · Exercise / conversion · Disposed 1,360 · Balance 2,640 F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
F2: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
F3: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 1,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004573 · ownership.xml · derivative · entry 3 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,640 Underlying: Common Stock · 1,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 700 | $21.38 | $14,966.00 |
DisclosureSEC source: 0001193125-26-004573 · ownership.xml · nonDerivative · entry 2 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,682 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 1,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-004573 · ownership.xml · nonDerivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 1,360 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-094576 · ownership.xml · derivative · entry 3 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 1,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 735 | $3.38 | $2,484.30 |
DisclosureSEC source: 0000950170-25-094576 · ownership.xml · nonDerivative · entry 2 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,022 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 1,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-094576 · ownership.xml · nonDerivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000950170-25-002811 · ownership.xml · derivative · entry 4 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2035-01-03 F4 · derivative.exercise_date: 25% of the shares subject to such option will vest and become exercisable on January 3, 2026 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionRestricted Stock Units · Derivative | 2,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002811 · ownership.xml · derivative · entry 3 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 2,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. F3 · derivative.exercise_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F3 · derivative.expiration_date: This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | SaleCommon Stock | 1,341 | $5.60 | $7,509.60 |
DisclosureSEC source: 0000950170-25-002811 · ownership.xml · nonDerivative · entry 2 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,397 F2 · kind: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | Exercise / conversionCommon Stock | 2,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002811 · ownership.xml · nonDerivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 44,100 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0000950170-24-114384 · ownership.xml · derivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,100 Underlying: Common Stock · 44,100 shares Expires 2034-10-09 F1 · derivative.exercise_date: The shares subject to such option vest in 48 equal monthly installments over four years from the Award Date, subject in each case to the grantee's continued service through the applicable vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantRestricted Stock Units · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-002433 · ownership.xml · derivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of Galecto, Inc. One-third of the restricted stock units subject to the award will vest on January 3, 2025 and the remaining restricted stock units will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001209191-23-001760 · doc4.xml · derivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 12:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 5,000 | $2.15 | $10,750.00 |
DisclosureSEC source: 0001209191-22-020682 · doc4.xml · nonDerivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,428 Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 22:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 287,500 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001209191-22-002215 · doc4.xml · derivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,500 Underlying: Common Stock · 287,500 shares Expires 2032-01-03 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 13:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 4,500 | $3.50 | $15,750.00 |
DisclosureSEC source: 0001209191-21-063798 · doc4.xml · nonDerivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,428 Read SEC document |
| June 24, 2021 Filed Jun 24, 2021 20:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | PurchaseCommon Stock | 3,000 | $5.11 | $15,330.00 |
DisclosureSEC source: 0001209191-21-042986 · doc4.xml · nonDerivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,928 Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 21:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002476 · doc4.xml · derivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2031-01-05 F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 5, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 01:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionSeries C-1 Preferred Stock · Derivative | 5,359 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-030412 · doc4.xml · derivative · entry 4 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 01:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | ConversionCommon Stock | 13,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030412 · doc4.xml · nonDerivative · entry 1 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date. Read SEC document |
| October 07, 2020 Filed Nov 5, 2020 01:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 519,940 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0000899243-20-030412 · doc4.xml · derivative · entry 3 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,940 Underlying: Common Stock · 519,940 shares Expires 2030-10-06 F2 · derivative.exercise_price: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F5 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F4 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on September 27, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F2 · balance_after: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. Read SEC document |
| June 24, 2020 Filed Nov 5, 2020 01:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 207,976 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000899243-20-030412 · doc4.xml · derivative · entry 2 Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,976 Underlying: Common Stock · 207,976 shares Expires 2030-06-24 F2 · derivative.exercise_price: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F5 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F3 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on October 22, 2019 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F2 · balance_after: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.